Mr. Michael Curtis serves as the Chief Development Officer of Ataxion. He also served as an Entrepreneur-in-Residence for Atlas Ventures. Prior to joining Ataxion, Dr. Curtis was Senior Vice President of Product Development and Regulatory Affairs at Catabasis Pharmaceuticals with responsibility for all as aspects of moving the company's products from research into clinical development. He was previously Vice President of Pharmaceutical Development at Infinity Pharmaceuticals, where he was responsible for manufacturing, formulation, analytical characterization and drug metabolism/pharmacokinetics. Prior to Infinity he was with Transkayotic Therapies (currently Shire), where he was responsible for analytical methods development and validation to support the registration of Elaprase® (idursulfase). Dr. Curtis was previously the Associate Director of Analytical Development at Syntonix Pharmaceuticals (currently Biogen IDEC), where he was involved with advancing the Transceptor™ technology which has resulted in the development of Eloctate™ (rFVIIFc) and Alprolix™ (rFIXFc). Before Syntonix, he was a member of the Therapeutic Protein Research Group at Genzyme, working on the development of the enzyme replacement therapy Myozyme® (alglucosidasealfa). Dr. Curtis began his career at Bristol-Myers Squibb, with positions of increasing responsibility working in small molecule and biologics development, most significantly on the manufacturing processes for Capoten® (captopril), Taxol® (paclitaxel) and the early development of Orencia® (abatacept). Dr. Curtis holds a Ph.D. in cell and molecular biology from Upstate Medical University and a B.S. in biochemistry from the State University of New York College of Environmental Science and Forestry.